Clinical Trial Update: A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing MRG002 to investigator's choice chemotherapy in HER2-positive unresectable advanced or metastatic urothelial cancer is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Urothelial Cancer

Drugs mentioned

• MRG002

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Advanced or Metastatic Urothelium Cancer | Phase 3 | Status: RECRUITING